Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis and Risk Factors for Progression Including Younger Age at Diagnosis or Higher Liver Stiffness in the Pivotal RESPONSE Study

Conference Reports for NATAP

EASL - European Association
for the Study of the Liver
Barcelona, Spain
May 27-30, 2026


Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis and Risk Factors for Progression Including Younger Age at Diagnosis or Higher Liver Stiffness in the Pivotal RESPONSE Study

	EASL 2026 May 26-30 Barcelona Marlyn J. Mayo1,